medigraphic.com
Boletín Médico del Hospital Infantil de México

2012, Número 4

<< Anterior Siguiente >>

Bol Med Hosp Infant Mex 2012; 69 (4)


Tos ferina, un problema vigente de salud pública en México. Planteamiento de la necesidad para introducir una nueva vacuna

Suárez-Idueta L, Herbas-Rocha I, Gómez-Altamirano CM, Richardson-López CV

Idioma: Español
Referencias bibliográficas: 57
Paginas: 314-320
Archivo PDF: 140.49 Kb.


RESUMEN

A pesar de la vacunación contra B. pertussis, se sigue reportando un gran número de muertes por tos ferina a nivel mundial. La pérdida de la inmunidad a través de los años y el incremento de la incidencia en adolescentes y adultos han sustentado el papel de estos grupos de edad en la transmisión de la enfermedad. Diversos países han implementado nuevas estrategias de vacunación con la finalidad de reducir su transmisión y significado clínico. En México, la tos ferina es un problema de salud pública vigente, y su control presenta algunos obstáculos, como la sospecha clínica fuera de la etapa del lactante, la confirmación del diagnóstico, los esquemas de vacunación tardíos o incompletos y la dificultad para limitar su transmisibilidad. La introducción de nuevas estrategias de vacunación en adolescentes y adultos, así como en las mujeres embarazadas, contribuirían al control de la enfermedad y limitarían sus complicaciones.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. American Academy of Pediatrics Committee on Infectious Diseases, Larry K. Pickering. Red Book: Informe del Comité de Enfermedades Infecciosas para 2003. México: Intersistemas; 2004. pp. 586-588.

  2. World Health Organization. Centers for Disease Control and Prevention. Vaccine preventable deaths and the global immunization vision and strategy, 2006-2015. MMWR 2006;55:511-515. Disponible en: http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5518a4.htm.

  3. Plotkin S. Aims, scope and findings of the global pertussis initiative. Pediatr Infect Dis J 2005;24(suppl 5):S5-S6.

  4. World Health Organization. Pertussis vaccines: WHO position paper. Wkly Epidemiol Rec 2010;85:385-400. Disponible en: http://www.who.int/wer/2010/wer8540.pdf.

  5. Wood N, McIntyre P. Pertussis: review of epidemiology, diagnosis, management and prevention. Paediatr Respir Rev 2008;9:201-211; quiz 211-212. Disponible en: http://www.sepeap.org/archivos/pdf/10885.pdf.

  6. Tanaka M, Vitek CR, Pascual FB, Bisgard KM, Tate JE, Murphy TV. Trends in pertussis among infants in the United States, 1980-1999. JAMA 2003;290:2968-2975.

  7. Mooi FR, van Loo IH, King AJ. Adaptation of Bordetella pertussis to vaccination: a cause for its reemergence? Emerg Infect Dis 2001;7(3 suppl):526-528.

  8. Tan T, Trindade E, Skowronski D. Epidemiology of pertussis. Pediatr Infect Dis J 2005;24(suppl 5):S10-S18.

  9. Singh M, Lingappan K. Whooping cough: the current scene. Chest 2006;130:1547-1553.

  10. Halperin SA. Pertussis immunization for adolescents: what are we waiting for? Can J Infect Dis.2001;12:74-76.

  11. Edwards KM. Overview of pertussis: focus on epidemiology, sources of infection, and long term protection after infant vaccination. Pediatr Infect Dis J 2005;24(suppl 6):S104-S108.

  12. Dirección General de Epidemiología. Manuales Simplificados Enfermedades Prevenibles por Vacunación. Secretaría de Salud. México; 2005.

  13. Dirección General de Epidemiología. Programa de Acción Sistema Nacional de Vigilancia Epidemiológica SINAVE. Secretaría de Salud. México; 2001.

  14. Anuarios de morbilidad. Dirección General de Epidemiología. Secretaría de Salud.

  15. Guiso N, Wirsing von König CH, Forsyth K, Tan T, Plotkin SA. The Global Pertussis Initiative: report from a round table meeting to discuss the epidemiology and detection of pertussis, Paris, France, 11-12 January 2010. Vaccine 2011;29:1115-1121.

  16. Quinn HE, McIntyre PB. The impact of adolescent pertussis immunization, 2004-2009: lessons from Australia. Bull World Health Organ 2011;89:666-674.

  17. Rivest P, Richer F, Bédard L. Difficulties associated with pertussis surveillance. Can Commun Dis Rep 2004;30:29-33,36.

  18. Crespo I, Cardeñosa N, Godoy P, Carmona G, Sala MR, et al. Epidemiology of pertussis in a country with high vaccination coverage. Vaccine 2011;29:4244-4248.

  19. Wymann MN, Richard JL, Vidondo B, Heininger U. Prospective pertussis surveillance in Switzerland, 1991-2006. Vaccine 2011;29:2058-2065.

  20. Sapián-López LA, Valdespino JL, Salvatierra B, Tapia-Conyer R, Gutiérrez G, Macedo J, et al. Seroepidemiology of whooping cough in Mexico. Salud Publica Mex1992;34:177-185.

  21. Sandoval PT, Arreola L del P, Quechol GR, Gallardo HG. Bordetella pertussis in adolescent students in Mexico City. Rev Saude Publica 2008;42:679-683.

  22. Ruiz Palacios, et al. A prospective cohort study of pertussis in adolescents attending middle school in Mexico City (ICAAC 2010). Datos no publicados.

  23. Centro Nacional para la Salud de la Infancia y la Adolescencia. Manual de Vacunación 2008-2009. Secretaria de Salud. México; 2008.

  24. Organización Mundial de la Salud. Estadísticas Sanitarias Mundiales; 2010. Disponible en: http://www.who.int/whosis/whostat/ES_WHS10_Full.pdf

  25. WHO/UNICEF. Regional Global Coverage; 2010. Disponible en: http://www.who.int/immunization_monitoring/routine/immunization_coverage/en/index4.html

  26. Instituto Nacional de Salud Pública. Encuesta Nacional de Cobertura de Vacunación. Informe Final de Resultados. México; 2010.

  27. Bisgard KM, Rhodes P, Connelly BL, Bi D, Hahn C, Patrick S, et al. Pertussis vaccine effectiveness among children 6 to 59 months of age in the United States, 1998-2001. Pediatrics 2005;116:e285-e294.

  28. Juretzko P, von Kries R, Hermann M, Wirsing von König CH, Weil J, Giani G. Effectiveness of acellular pertussis vaccine assessed by hospital-based active surveillance in Germany. Clin Infect Dis 2002;35:162-167.

  29. Salmaso S, Mastrantonio P, Tozzi AE, Stefanelli P, Anemona A, CiofidegliAtti ML, et al. Sustained efficacy during the first 6 years of life of 3-component acellular pertussis vaccines administered in infancy: the Italian experience. Pediatrics 2001;108:e81.

  30. Gustafsson L, Hessel L, Storsaeter J, Olin P. Long-term follow-up of Swedish children vaccinated with acellular pertussis vaccines at 3, 5, and 12 months of age indicates the need for a booster dose at 5 to 7 years of age. Pediatrics 2006;118:978-984.

  31. Wendelboe AM, Van Rie A, Salmaso S, Englund JA. Duration of immunity against pertussis after natural infection or vaccination. Pediatr Infect Dis J 2005;24(suppl 5):S58-S61.

  32. Jenkinson D. Duration of effectiveness of pertussis vaccine: evidence from a 10 year community study. Br Med J (Clin Res Ed) 1988;296:612-614.

  33. Ramsay ME, Farrington CP, Miller E. Age-specific efficacy of pertussis vaccine during epidemic and non-epidemic periods. Epidemiol Infect 1993;111:41-48.

  34. Van Buynder PG, Owen D, Vurdien JE, Andrews NJ, Matthews RC, Miller E. Bordetella pertussis surveillance in England and Wales: 1995-7. Epidemiol Infect 1999;123:403-411.

  35. Tindberg Y, Blennow M, Granström M. A ten year follow-up after immunization with a two component acellular pertussis vaccine. Pediatr Infect Dis J 1999;18:361-365.

  36. Lugauer S, Heininger U, Cherry JD, Stehr K. Long-term clinical effectiveness of an acellular pertussis component vaccine and a whole cell pertussis component vaccine. Eur J Pediatr 2002;161:142-146.

  37. Kowalzik F, Barbosa AP, Fernandes VR, Carvalho PR, Avila-Aguero ML, et al. Prospective multinational study of pertussis infection in hospitalized infants and their household contacts. Pediatr Infect Dis J 2007;26:238-242.

  38. Wendelboe AM, Njamkepo E, Bourillon A, Floret DD, Gaudelus J, Gerber M, et al. Transmission of Bordetella pertussis to young infants. Pediatr Infect Dis J 2007;26:293-299.

  39. Bisgard KM, Pascual FB, Ehresmann KR, Miller CA, Cianfrini C, Jennings CE, et al. Infant pertussis: who was the source? Pediatr Infect Dis J 2004;23:985-989.

  40. Deen JL, Mink CA, Cherry JD, Christenson PD, Pineda EF, Lewis K, et al. Household contact study of Bordetella pertussis infections. Clin Infect Dis 1995;21:1211-1219.

  41. Elliott E, McIntyre P, Ridley G, Morris A, Massie J, McEniery J, et al. National study of infants hospitalized with pertussis in the acellular vaccine era. Pediatr Infect Dis J 2004;23:246-252.

  42. Perret C, Viviani T, Peña A, Abarca K, Ferrés M. Source of infection in young infants hospitalized with Bordetella pertussis. Rev Med Chil 2011;139:448-454.

  43. Broder KR, Cortese MM, Iskander JK, Kretsinger K, Slade BA, Brown KH, et al. Preventing tetanus, diphtheria, and pertussis among adolescents: use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccines recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2006;55(RR-3):1-34.

  44. Ward JI, Cherry JD, Chang SJ, Partridge S, Lee H, Treanor J, et al. Efficacy of an acellular pertussis vaccine among adolescents and adults. N Engl J Med 2005;353:1555-1563.

  45. Edelman K, He Q, Mäkinen J, Sahlberg A, Haanperä M, Schuerman L, et al. Immunity to pertussis 5 years after booster immunization during adolescence. Clin Infect Dis 2007;44:1271-1277.

  46. Ulloa-Gutierrez R, Hozbor D, Avila-Aguero ML, Caro J, Wirsing von König CH, Tan T, et al. The global pertussis initiative: meeting report from the Regional Latin America Meeting, Costa Rica, 5-6 December, 2008. Hum Vaccin 2010;6:876-880.

  47. Updated recommendations for use of tetanus toxoid, reduced diphteria toxoid and acellular pertussis vaccine (Tdap) in pregnant women and persons who have or anticipate having close contact with an infant aged <12 months. Advisory Committee on Immunization Practices (ACIP). CDC 2011;60:1424-1426. Disponible en: http://www.cdc.gov/mmwr/preview/mmwrhtml/mm6041a4.htm

  48. Wood N, Quinn HE, McIntyre P, Elliott E. Pertussis in infants: preventing deaths and hospitalizations in the very young. J Paediatr Child Health 2008;44:161-165.

  49. Ulloa-Gutiérrez R. Estrategias actuales de vacunación contra tos ferina en niños y adultos. Acta Pediátrica Costarricense 2009;20:81-87.

  50. Kandola K, Lea A, White W, Santos M. A comparasion of pertussis rates in the Northwest Territories: pre- and postacellular pertussis vaccine introduction in children and adolescents. Can J Infect Dis Med Microbiol 2005;16:271-274.

  51. Mooi FR, de Greeff SC. The case for maternal vaccination against pertussis. Lancet Infect Dis 2007;7:614-624.

  52. Shakib JH, Ralston S, Raissy HH, Stoddard GJ, Edwards KM, Byington CL. Pertussis antibodies in postpartum women and their newborns. J Perinatol 2010;30:93-97.

  53. Gall SA, Myers J, Pichichero M. Maternal immunization with tetanus-diphtheria-pertussis vaccine: effect on maternal and neonatal serum antibody levels. Am J Obstet Gynecol 2011;204:334.e1-e5.

  54. Leuridan E, Hens N, Peeters N, de Witte L, Van der Meeren O, Van Damme P. Effect of a pre-pregnancy pertussis booster dose on maternal antibody titers in young infants. Pediatr Infect Dis J 2011;30:608-610.

  55. Van Savage J, Decker MD, Edwards KM, Sell SH, Karzon DT. Natural history of pertussis antibody in the infant and effect on vaccine response. J Infect Dis 1990;161:487-492.

  56. Ward JI, Cherry JD, Chang SJ, Partridge S, Keitel W, Edwards K, et al. Bordetella pertussis infections in vaccinated and unvaccinated adolescents and adults, as assessed in a national prospective randomized Acellular Pertussis Vaccine Trial (APERT). Clin Infect Dis 2006;43:151-157.

  57. Van Rie A, Wendelboe AM, Englund JA. Role of maternal pertussis antibodies in infants. Pediatr Infect Dis J 2005;24(5 suppl):S62-S65.




2020     |     www.medigraphic.com